Antonio Palumbo, Hervé Avet-Loiseau, Stefania Oliva, Henk M Lokhorst, Hartmut Goldschmidt, Laura Rosinol, Paul Richardson, Simona Caltagirone, Juan José Lahuerta, Thierry Facon, Sara Bringhen, Francesca Gay, Michel Attal, Roberto Passera, Andrew Spencer, Massimo Offidani, Shaji Kumar, Pellegrino Musto, Sagar Lonial, Maria T Petrucci, Robert Z Orlowski, Elena Zamagni, Gareth Morgan, Meletios A Dimopoulos, Brian G M Durie, Kenneth C Anderson, Pieter Sonneveld, Jésus San Miguel, Michele Cavo, S Vincent Rajkumar, Philippe Moreau
PURPOSE: The clinical outcome of multiple myeloma (MM) is heterogeneous. A simple and reliable tool is needed to stratify patients with MM. We combined the International Staging System (ISS) with chromosomal abnormalities (CA) detected by interphase fluorescent in situ hybridization after CD138 plasma cell purification and serum lactate dehydrogenase (LDH) to evaluate their prognostic value in newly diagnosed MM (NDMM). PATIENTS AND METHODS: Clinical and laboratory data from 4,445 patients with NDMM enrolled onto 11 international trials were pooled together...
September 10, 2015: Journal of Clinical Oncology